2023 Strategic Grant (SG)

Pharmacoproteomics to prevent side effects of BACE inhibitors for Alzheimer‘s disease

Stefan Lichtenthaler
German Center for Neurodegenerative Diseases (Deutsches Zentrum für Neurodegenerative Erkrankungen - DZNE)
Bonn, Germany

The BACE1 (beta-secretase 1) protein has been indentified as a potential drug therapy to treat Alzheimer's disease. However, in advanced clinical trials, medications to inhibit BACE1 were found to cause adverse side effects, including mild cognitive decline. Dr. Stefan Lichtenthaler and colleages will study the CSF of participants from 4 different BACE1 phase 2/3 clinical trials to understand the pathway for these side effects and help to optimize the safe dosing of BAC inhibitors in future AD prevention trials.